Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.  The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.  Choi (necrotic) responses were more commonly observed in patients treated at higher doses.  In addition, intravenous infusion of JX-594 was safe and well-tolerated.  These data were presented today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington DC.

"These data represent a significant milestone for the field of oncology and viral therapy as this is the first time that a viral or genetic product has demonstrated reproducible, biopsy-proven delivery to multiple solid tumor types following intravenous administration," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We look forward to extending our experience with IV JX-594 in our planned Phase 3 trial in patients with advanced liver cancer.  This pivotal trial will utilize both IV and targeted intratumoral injections of JX-594 to maximize potential patient benefit.  We expect to initiate this study in Q4 of 2010."

"JX-594 represents a promising potential treatment option for patients with multiple types of cancer.  As the first intravenous biological immunotherapy to demonstrate safety and tumor-specific delivery, JX-594 may add significantly to the armamentarium for many solid tumors," stated '/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. (OTCQB: ... 400 million people worldwide are living with diabetes, with  ... by 2030.  The global market for diabetes treatments is ... 330,000 people worldwide died from pancreatic cancer.  Pancreatic cancer ... to cancer in the United States ...
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Twelve-Week Maintenance DosingBEERSE, Belgium, Jan. 22 ... a new class of biologics, has been approved by ... approved indication of ustekinumab is for the treatment of ... to respond to, or who have a contraindication to, ...
... Cell Innovations, Inc., (SCLL.PK) announced today that it has filed a new ... cells. , ... Houston, TX (PRWEB) January 22, 2009 -- Stem Cell ... application for the production of pluripotent stem cells from primordial germ cells. ...
... for testing the quality of a sperm before it ... conception. , Researchers at the University of Edinburgh, funded ... have created a way of chemically ,fingerprinting, individual sperm ... consider whether the sperm is healthy enough to be ...
Cached Biology Technology:New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 2New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 3New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 4Stem Cell Innovations, Inc., Files New Patent Application 2Stem Cell Innovations, Inc., Files New Patent Application 3New sperm shaker to improve IVF success 2
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... hormone-like compounds linked to the consumption of soy-based foods ... brain, resulting in early-onset puberty and symptoms of advanced ... by researchers at North Carolina State University. The study ... cause reproductive health problems, as well as in providing ...
... a drug to achieve normal levels of blood ... high insulin levels. If this approach succeeds in ... children with congenital hyperinsulinism, a rare but potentially ... dangerously high. "There is currently no effective ...
... that measure pressure within the eye and dispense ... new material developed by biomedical engineers at UC ... engineering, and postdoctoral researcher Hailin Cong started with ... method for placing powdered silver on the PDMS ...
Cached Biology News:New study shows compounds from soy affect brain and reproductive development 2Treatment corrects severe insulin imbalance in animal studies 2Treatment corrects severe insulin imbalance in animal studies 3
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
ERalpha (Ser 104/106)...
Biology Products: